Skip to main content

Table 1 Characteristics of studies included in the analyses

From: Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Author, year

Design

Vaccination status£*

Vaccine strain

Number of HI titre intervals$

Drop-out rate#

  

Vaccinated

Unvaccinated

Unknown

   

Bell et al., 1957 [32]

Challenge

32 (14)

-

 

A

3

> 10%

Clark et al., 1983a [33]

Challenge

49 (7)

23 (16)

 

A

6

≤ 10%

Clark et al., 1983b [34]

Challenge

39 (6)

58 (23)

 

A

5

≤ 10%

Dowdle et al., 1973 [35]

Trial

227 (90)

  

A

4

≤ 10%

Eaton and Meiklejohn, 1945 [36]

Trial

94 (4)

145 (9)

 

A(Olson)

5

≤ 10%

  

94 (9)

145 (4)

 

A(PR8)

  
  

94 (9)

145 (4)

 

B

  

Evans, 1975 [37]

Cohort

696 (262)

-

 

A

5

NA

  

346 (47)

  

B

  

Farnik and Bruj, 1966 [38]

Cohort

-

248 (52)

 

A

5

≤ 10%

Fox et al., 1982 [39]

Cohort

-

-

222 (13)

A(H1N1)

4

≤ 10%

    

343 (98)

A(H3N2)

3

 
    

140 (28)

B

3

 

Goodeve et al., 1983 [40]

Challenge

97 (9)

23 (15)

 

B

6

≤ 10%

Greenberg, Couch and Kasel, 1974 [41]

Cohort

-

212 (97)

 

A

5

≤ 10%

Hirota et al., 1997 [24]

Trial

84 (4)

118 (9)

 

A(H1N1)

3

≤ 10%

  

84 (4)

118 (9)

 

A(H3N2)

  
  

84 (4)

118 (9)

 

B

  

Hobson et al., 1972 [5]

Challenge

  

106 (20)

A(Field Trial)

9

NA

    

345 (166)

A(HK Salisbury)

  
  

-

-

119 (62)

A(Pre-1968)

  
    

462 (135)

B

  

Meiklejohn et al., 1952 [42]

Trial

-

101 (5)

 

A

6

> 10%

Potter et al., 1977 [43]

Challenge

134 (26)

-

 

A

6

≤ 10%

Salk et al., 1945 [8]

Trial

82 (2)

246 (21)

 

A(Weiss)

10

> 10%

  

82 (2)

144 (12)

 

A(PR8)

  
  1. *: Number of observations (number of influenza cases)
  2. $. Number of reported intervals on pre-season HI titres.
  3. £ Vaccination performed just before exposure
  4. # Number of subjects analyzed/Number of subjects included in the analysis